Trial record 41 of 81 for:    "phenylketonuria"

GMP Drink for PKU Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT02915510
Recruitment Status : Recruiting
First Posted : September 27, 2016
Last Update Posted : November 1, 2017
Information provided by (Responsible Party):
Nutricia UK Ltd

Brief Summary:
This study will evaluate the safety, gastrointestinal (GI) tolerance, acceptability and compliance of a Glycomacropeptide-based protein substitute for patients with Phenylketonuria (PKU).

Condition or disease Intervention/treatment Phase
Phenylketonuria Dietary Supplement: Glycomacropeptide-based protein substitute Not Applicable

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 80 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Supportive Care
Official Title: Evaluating the Tolerance, Safety and Acceptability of PKU GMPro, a Whey Protein Derived Feed for the Dietary Management of Phenylketonuria in Children and Adults - a Pilot Trial
Study Start Date : July 2016
Estimated Primary Completion Date : August 2018
Estimated Study Completion Date : August 2018

Arm Intervention/treatment
Experimental: GMP
Single arm designed, 3 day baseline, 28day on GMP
Dietary Supplement: Glycomacropeptide-based protein substitute

Primary Outcome Measures :
  1. Blood Phenylalanine (and other amino acids) [ Time Frame: 3 points throughout 28 days ]
    Blood spot test

Secondary Outcome Measures :
  1. Gastro-intestinal tolerance questionaire [ Time Frame: 12/31 days ]
    Questionaire detailing any GI symptoms, severity and change from usual

  2. Product compliance questionaire [ Time Frame: 31 days ]
    Breif questionaire on amounts offered and amounts actually consumed, compared to recomended amount.

  3. Product acceptability questionnaire [ Time Frame: 2/31 days ]
    Breif tick-box questionaire on overal liking and acceptability of product

  4. Patient reproted nutrient intake (3 day food diaries) [ Time Frame: 6/31 days ]
    3 day food diaries, subsequently analysed in dietary software.

  5. Pateint-reported appetite (visual analogue scale) [ Time Frame: 6/31 days ]
    Measures of overal appetite and satiety via visual analouge scale

  6. Antropometry (hieight and weight) [ Time Frame: 2/31 days ]
    Measurements of height and weight at baseline and end of study

  7. Safety (Adverse events reporting) [ Time Frame: 31 days ]
    Reporting of adverse events throughout study

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   3 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male or female
  • Over 3 years of age
  • Diagnosed with classical or variant type phenylketonuria
  • Have been compliant in taking at least one amino acid-based, Phe-free protein substitute, providing at least 20g protein equivalents, for at least 1 month prior to trial commencement
  • Have a prescribed daily Phe allowance
  • Written informed consent from patient, or from parent / carer if applicable

Exclusion Criteria:

  • Currently prescribed Sapropterin or similar tetrahydrobiopterin based medication
  • Pregnant or lactating
  • Requiring parenteral nutrition
  • Major hepatic or renal dysfunction
  • Participation in other studies within 1 month prior to entry of this study
  • Allergy to any of the study product ingredients, including milk protein or soya
  • Investigator concern around willingness/ability of patient or parent/carer to comply with protocol requirements

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02915510

Contact: Robert Browne, BSc

United Kingdom
Great Ormond Street Hospital Not yet recruiting
London, United Kingdom
Contact: Rachel Skeath         
Guy's and St Thomas' NHS Fondation Trust Recruiting
London, United Kingdom
Contact: Carla Fitzachary         
UCLH Not yet recruiting
London, United Kingdom
Contact: Charlotte Ellerton         
Royal Manchester Children's Hospital Not yet recruiting
Manchester, United Kingdom
Contact: Karen van Wyk         
Sheffield Teaching Hospital Recruiting
Sheffield, United Kingdom
Contact: Melanie Hill         
Sponsors and Collaborators
Nutricia UK Ltd
Study Director: Rebecca Stratton, PHd Nutricia Ltd UK

Responsible Party: Nutricia UK Ltd Identifier: NCT02915510     History of Changes
Other Study ID Numbers: GMP2016
First Posted: September 27, 2016    Key Record Dates
Last Update Posted: November 1, 2017
Last Verified: October 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Additional relevant MeSH terms:
Brain Diseases, Metabolic, Inborn
Brain Diseases, Metabolic
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Amino Acid Metabolism, Inborn Errors
Metabolism, Inborn Errors
Genetic Diseases, Inborn
Metabolic Diseases